Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod effects on functional brain adaptation in relapsing-remitting multiple sclerosis
NL-OMON44409Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fingolimod in multiple sclerosis (MS), sponsored by Vrije University Medical Center. Primary endpoints: Changes in brain activity and brain networks, Changes in cognition and 1 more. Started Feb 2015; status: active, not recruiting.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON44409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44409.